Duncan J. Stewart

Duncan J. Stewart

Auto-generated profile, based on publicly available information

Duncan J. Stewart

Ottawa Hospital Research Institute

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CEColin E. Evans
Colin E. Evans
NCNicholas D. Cober
Nicholas D. Cober
ZDZhiyu Dai
Zhiyu Dai
DSDuncan J. Stewart
Duncan J. Stewart
YZYouyang Zhao
Youyang Zhao
Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and development of plexiform lesions. PAH vasculopathy leads to progressive increases in pulmonary vascular resistance, right heart failure and, ultimately, premature death. Besides other cell types that are known to be involved in PAH pathogenesis (e.g.smooth muscle cells, fibroblasts and leukocytes), recent studies have demonstrated that endothelial cells (ECs) have a crucial role in the initiation and progression of PAH. The EC-specific role in PAH is multi-faceted and affects numerous pathophysiological processes, including vasoconstriction, inflammation, coagulation, metabolism and oxidative/nitrative stress, as well as cell viability, growth and differentiation. In this review, we describe how EC dysfunction and cell signalling regulate the pathogenesis of PAH. We also highlight areas of research that warrant attention in future studies, and discuss potential molecular signalling pathways in ECs that could be targeted therapeutically in the prevention and treatment of PAH.

1 June 2009 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
DSDuncan J Stewart
Duncan J Stewart
MKMichael Jb Kutryk
Michael Jb Kutryk
DFDavid Fitchett
David Fitchett
MFMichael Freeman
Michael Freeman
NCNancy Camack
Nancy Camack
SRSam Radhakrishnan
Sam Radhakrishnan
Despite the promise of proangiogenic gene therapy most clinical trials have failed to show benefit for the primary end point analysis. The NOGA angiogenesis Revascularization Therapy: assessment by RadioNuclide imaging (NORTHERN) trial was a double-blind, placebo-controlled study of intramyocardial vascular endothelial growth factor (VEGF165) gene therapy versus placebo, involving seven sites across Canada, designed to overcome major limitations of previous proangiogenic gene therapy trials. A total of 93 patients with refractory Canadian Cardiovascular Society (CCS) class 3 or 4 anginal symptoms were randomized to receive 2,000 µg of VEGF plasmid DNA or placebo (buffered saline) delivered via the endocardial route using an electroanatomical NOGA guidance catheter. There was no difference between the VEGF-treated and the placebo groups in the primary end point of change in myocardial perfusion from baseline to 3 or 6 months, assessed by single photon emission tomography (SPECT) imaging, although a significant reduction in the ischemic area was seen in both groups. Also, similar improvements in exercise treadmill time and anginal symptoms were seen in the VEGF and the placebo groups at 3 and 6 months, although again there were no differences between these groups. Despite the intramyocardial administration of a high “dose” of plasmid DNA using a percutaneous guidance catheter system, there was no benefit of VEGF gene therapy at 3 or 6 months for any of the end points studied.

1 February 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LMLauralyn A. McIntyre
Lauralyn A. McIntyre
DSDuncan J. Stewart
Duncan J. Stewart
SMShirley H. J. Mei
Shirley H. J. Mei
DCDavid Courtman
David Courtman
IWIrene Watpool
Irene Watpool
DFDean A. Fergusson
Dean A. Fergusson
Rationale: In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death. Objectives: To conduct a phase I dose escalation trial of MSCs in septic shock with the primary objective of examining the safety and tolerability of MSCs. Methods: We enrolled nine participants within 24 hours of admission to the ICU. A control cohort of 21 participants was enrolled before starting the MSC interventional cohort to characterize expected adverse events (AEs) and to serve as a comparator for the intervention cohort. Three separate MSC dose cohorts, with three participants per cohort, received a single intravenous dose of 0.3, 1.0, and 3.0 × 106 cells/kg. A prespecified safety plan monitored participants for the occurrence of AEs; cytokines were collected at prespecified time points. Measurements and Main Results: Ages of participants in the interventional versus observational cohorts were median of 71 (range, 38–91) and 61 (range, 23–95). Acute Physiology and Chronic Health Evaluation scores were median of 25 (range, 11–28) and 26 (range, 17–32). MSC doses ranged from 19 to 250 million cells. There were no prespecified MSC infusion–associated or serious unexpected AEs, nor any safety or efficacy signals for the expected AEs or the measured cytokines between the interventional and observational cohorts. Conclusions: The infusion of freshly cultured allogenic bone marrow–derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe. Clinical trial registered with www.clinicaltrials.gov (NCT02421484).

11 September 2015 in Circulation Research
Verified
Journal Article
Open access
PDF file
JGJohn Granton
John Granton
DLDavid Langleben
David Langleben
MKMichael B. Kutryk
Michael B. Kutryk
NCNancy Camack
Nancy Camack
JGJacques Galipeau
Jacques Galipeau
DSDuncan J. Stewart
Duncan J. Stewart
Rationale: Pulmonary arterial hypertension (PAH) remains a progressive and eventually lethal disease characterized by increased pulmonary vascular resistance due to loss of functional lung microvasculature, primarily at the distal (intracinar) arteriolar level. Cell-based therapies offer the potential to repair and regenerate the lung microcirculation and have shown promise in pre-clinical evaluation in experimental models of PAH.

26 September 2018 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
MLManoj M. Lalu
Manoj M. Lalu
SMSasha Mazzarello
Sasha Mazzarello
JZJennifer Zlepnig
Jennifer Zlepnig
YDYuan Yi (Ryan) Dong
Yuan Yi (Ryan) Dong
JMJoshua Montroy
Joshua Montroy
DFDean A. Fergusson
Dean A. Fergusson
Preclinical and clinical evidence suggests that mesenchymal stem cells (MSCs) may be beneficial in treating both acute myocardial infarction (AMI) and ischemic heart failure (IHF). However, the safety profile and efficacy of MSC therapy is not well‐known. We conducted a systematic review of clinical trials that evaluated the safety or efficacy of MSCs for AMI or IHF. Embase, PubMed/Medline, and Cochrane Central Register of Controlled Trials were searched from inception to September 27, 2017. Studies that examined the use of MSCs administered to adults with AMI or IHF were eligible. The Cochrane risk of bias tool was used to assess bias of included studies. The primary outcome was safety assessed by adverse events and the secondary outcome was efficacy which was assessed by mortality and left ventricular ejection fraction (LVEF). A total of 668 citations were reviewed and 23 studies met eligibility criteria. Of these, 11 studies evaluated AMI and 12 studies evaluated IHF. There was no association between MSCs and acute adverse events. There was a significant improvement in overall LVEF in patients who received MSCs (SMD 0.73, 95% CI 0.24–1.21). No significant difference in mortality was noted (Peto OR 0.68, 95% CI 0.38–1.22). Results from our systematic review suggest that MSC therapy for ischemic heart disease appears to be safe. There is a need for a well‐designed adequately powered randomized control trial (with rigorous adverse event reporting and evaluations of cardiac function) to further establish a clear risk‐benefit profile of MSCs. Stem Cells Translational Medicine 2018

13 July 2020 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JOJulie Ouellette
Julie Ouellette
XTXavier Toussay
Xavier Toussay
CCCesar H. Comin
Cesar H. Comin
LCLuciano da F. Costa
Luciano da F. Costa
MHMirabelle Ho
Mirabelle Ho
BLBaptiste Lacoste
Baptiste Lacoste